Biosense Webster, Inc.

Biosense Webster, Inc., a subsidiary of Ethicon, Inc. (Johnson & Johnson), manufactures and supplies cardiac electrophysiology medical devices—diagnostic and ablation catheters, cardiac mapping systems, and related electrophysiology equipment—primarily to the Department of Veterans Affairs, Defense Health Agency, and Department of the Army Medical Command on a full-and-open, unrestricted commercial basis with no set-aside participation.

Biosense Webster operates from Irvine, California as a pure-play federal contractor under NAICS 339112 (Surgical and Medical Instrument Manufacturing) and PSC J001 (Medical and Surgical Instruments, Equipment, and Supplies), with a footprint of 3,868 prime awards totaling $460.8 million in combined potential value across 31 distinct customer agencies. The vendor holds no subcontract relationship in the source data—100% of awards are prime contracts and indefinite delivery vehicles. The firm competes exclusively in full-and-open procurement; no set-aside designations appear across the award history. Recent activity has grown modestly from 37 awards in 2022 to 43 in 2025, with 14 awards recorded in 2026 year-to-date. Roughly 28% of the award count concentrates in the top five VA Veterans Integrated Service Networks (VISNs 10, 12, 8, 6, and 22), though dollar concentration differs: the Defense Health Agency, Army Medical Command, and VISN 17 together account for 33% of combined potential value, indicating that while Biosense Webster distributes volume across many VISNs, larger-dollar programs sit with DoD and specific regional VA networks.

Biosense Webster's vehicle portfolio centers on single-award indefinite delivery contracts and blanket purchase agreements with long ceilings and multi-year runways. The $133.997 billion VA/Defense Health Agency Indefinite Delivery Contract (36C10G24D0058) for electrophysiology catheters and related cardiovascular devices, effective through March 31, 2029, anchors the portfolio; 36 task orders drawn against it total $26.3 million. The $64 million VA Blanket Purchase Agreement (VA11916A0066) for electrophysiology catheters generated 329 task orders worth $28 million combined. A $3 million Defense Health Agency Blanket Purchase Agreement for 3D mapping catheters (awarded October 2024, through November 2029) and a $2.25 million Defense Health Agency IDC for CARTO Catheterization Laboratory systems (October 2022, through September 2025) round out the major vehicles. The firm also holds smaller single-award BPAs and IDCs with individual VISNs for cardiac mapping equipment ($483,068 with VISN 9 through September 2030) and maintenance services across multiple regional networks.

Biosense Webster's concrete work comprises CARTO 3 cardiac mapping systems and electro-anatomical mapping hardware; VariPulse, ThermoCool SmartTouch, and other branded ablation and diagnostic catheters; cardiac catheterization laboratory equipment and accessories; preventive maintenance, emergency repair, and software upgrade services; and extended warranty coverage. Representative orders illustrate scope: a $7.549 million VISN 12 order (October 2025) for VariPulse catheters and cables; a $3.344 million VISN 17 order (April 2026) for assorted catheters; a $2.528 million VISN 17 order (June 2026) for J & J Healthcare Systems catheter systems; a $766.5 million VISN 17 purchase order (October 2022) for CARTO3 Service Plan covering three years; and dozens of sub-million, short-cycle orders for emergency repairs, component replacements, and software licenses at individual VA medical centers.

Recompete exposure in the next twenty-four months is moderate: 28 awards with combined potential value of $15.6 million reach their ultimate completion dates, representing about 3% of total combined potential value. The largest single-award vehicles—the $133.997 billion VA/DHA IDIQ and $64 million VA BPA—do not expire within this window and anchor the customer relationships, though specific task orders and smaller maintenance contracts cycle continuously. The Defense Health Agency Blanket Purchase Agreement for 3D mapping catheters (awarded October 2024) carries a ceiling that runs through November 2029, signaling sustained demand within the military healthcare network. Biosense Webster's reliance on sole-source procurement for CARTO 3 system-specific work (cited in multiple awards under FAR 6.302-2 and simplified acquisition sole-source authority) reflects original-equipment-manufacturer status and creates switching cost for customers, reducing competitive recompete risk on system maintenance and proprietary consumables but heightening sensitivity to technology refresh cycles and competitive alternative platform adoption across the VA.